1. Vos T et al. Global, regional, and national incidence, prevalence, and years lived with disability of 328 diseases and injuries in 195 countries from 1990 to 2016: Systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1211–59.
2. Mayo Clinic [Internet].heart failure[cited 2023 Aug 1]. Available from: https://www.mayoclinic.org/diseases-conditions/heart-failure/symptoms-causes/syc-20373142
3. Azad N, et al. Management of chronic heart failure in the elderly. J Geriator Cardiol. 2014;11(4):329–37.
4. Cao CW, et al. Circulation. 2023;147:e93-e621. PMID: 36695182
5. Heidenrich PA, et al. Circulation. 2022;145:e895-e1032. PMID: 35363499
6. Kosaraju A, et al. Left ventricular ejection fraction. [cited 2023 Aug 1]. In: StatPearls [Internet]. Treasure Island, Florida: StatPearls Publishing; from January 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459131/
7. Meyer ML, et al. Am J Health Syst Pharm 2022;79:1424-1430. PMID: 35524990
8. McDonough T et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur Heart J. 2021;00:1-128.
9. Noll NA, et al. Mouse models of heart failure with preserved or reduced ejection fraction. My name is J. Pasol. 2020 August;190(8):1596-1608.
10. American Heart Association [Internet].Types of heart failure [cited 2023 Aug 1]. Available from: https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/types-of-heart-failure
11. Severino P, et al. Characterization of myocardial tissue in heart failure with preserved ejection fraction: from histopathology and cardiac magnetic resonance findings to therapeutic targets. Int J Mol Sci. July 17, 2021;22(14)doi:10.3390/ijms22147650
12. Mayo Clinic [Internet].heart attack [cited 2023 Aug 1]. Available from: https://www.mayoclinic.org/diseases-conditions/heart-attacks/symptoms-causes/syc-20373106
13. Bozkurt B. Heart failure in other women. Methodist DeBakey. Cardio Basque J. 2017; 13 (4): 216-223.
14. Iorga A, et al. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. biological sex differences. 2017; 8:33.
15. DeFilippis EM, et al. Heart failure subtypes and cardiomyopathy in women. Circules. 2022:18;130(4):436-454.
16. American Heart Association [Internet].Women are found to have a higher risk of death from heart failure and heart attack than men [cited 2023 August 3]. Available from: https://newsroom.heart.org/news/women-found-to-be-at-higher-risk-for-heart-failure-and-heart-attach-death-than-men
17. Cleveland Clinic [Internet].cardiomyopathy [cited 2023 August 3]. Available from: https://my.clevelandclinic.org/health/diseases/16841-cardiomyopathy#:~:text=Cardiomyopathy%20can%20make%20your%20heart,can%20lead%20to%20heart%20failure
18. Ogina S, et al. Impact of cardiac amyloidosis patients in the HFpEF trial. jack. 2021;9:169-178. PMID: 33549560
19. H. Ando et al. Guidelines for clinicians on transthyretin-related hereditary amyloidosis. Orphanet J Raredis. 2013;8:31.
20. Lo S, et al. Cardiac transthyretin amyloidosis disease progression is indicated by the National Amyloidosis Center Transthyretin Amyloidosis Stage Continuous Calculation. ESC heart failure. 2020;7(6):3942-9.
21. Adams D, et al. Expert consensus recommendations to improve the diagnosis of ATTR amyloidosis with isolated neuropathy. J New Roll. 2021;268:2109-2122.
22. Nijst P, et al. Recent diagnostic advances in the management of amyloid cardiomyopathy. Faculty opinions. 2021;10:31.
23. Papinggiotis G, et al. Cardiac amyloidosis: epidemiology, diagnosis, and treatment. Electronic Journal of Cardiology Practice. 2021;19(19)
24. Desport, et al. AL amyloidosis. Orphanet J Raredis. 7, 54 (2012).
25. Rubin J Transcardial amyloidosis: overlooked, underdiagnosed, and treatable. annual review of medicine. 2020;71:203-219
26. Adams D, et al. Expert opinion on monitoring of symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet Rare Disease Journal. 2021
27. Manziari L, et al. Differences in clinical symptoms and findings between idiopathic dilated cardiomyopathy and ischemic cardiomyopathy in an unselected population of patients with heart failure. Open Cardio Basque Med J. 2012; 6: 98–105.
28. Mavrogeni S, et al. Cardiac involvement in Duchenne and Becker muscular dystrophies. World J Cardiol. 2015 July 26; 7(7): 410–414.
29. Schultheis HP, et al. Dilated cardiomyopathy. Nat Rev Dis Primer. 2019 May 9;5(1):32.
30. Bells DM. Interaction between heart excitation and contraction. Nature. 2002 Jan 10;415(6868):198-205.
31. Grote Beverborg N, et al. Phosphoranban antisense oligonucleotide improves cardiac function in mouse cardiomyopathy. Heart Failure 2021 Conference.
32. Povisil G, et al. Evaluating the role of rare genetic mutations in heart failure patients. JAMA Cardiol. 2021;6(4):379–386.
33. Workplace in Arizona. Acts on CKD’s internal programs and metrics. [Internet]. Accessed April 27, 2023. Available from https://astrazeneca.workplace.com/100025043435576/videos/684605172857664/
34. AstraZeneca (2023). Advancing UK life sciences through innovation and collaboration. [Brochure]
35. clinicaltrials.gov [Internet]. Optimization of digital diagnostic pathways for heart failure in the region (OPERA); [cited 2023 Aug 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04724200
36. University of Glasgow [Internet]. The Landmark Partnership aims to improve health in Scotland. [cited 2023 Aug 1]. Available from: https://www.gla.ac.uk/news/headline_876209_en.html
37. Poch, C.M. Such. Al. Migration and antifibrotic programs define the regenerative potential of human cardiac progenitor cells. nut. Cell Biol.
